Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A CXCR4 partial agonist improves immunotherapy by targeting immunosuppressive neutrophils and cancer-driven granulopoiesis.
Qian J, Ma C, Waterbury QT, Zhi X, Moon CS, Tu R, Kobayashi H, Wu F, Zheng B, Zeng Y, Zheng H, Ochiai Y, White RA, Harle DW, LaBella JS, Zamechek LB, ZhongMing Hu L, Moy RH, Han AS, Daugherty BL, Lederman S, Wang TC. Qian J, et al. Among authors: moy rh. Cancer Cell. 2025 Jun 21:S1535-6108(25)00256-9. doi: 10.1016/j.ccell.2025.06.006. Online ahead of print. Cancer Cell. 2025. PMID: 40578360
Claudin 18 immunohistochemistry in cholangiocarcinoma.
Desai N, Ko HM, Lee M, Fazlollahi L, Moy RH, Yoon SS, Remotti H, Levy B, Turk AT, Lagana SM. Desai N, et al. Among authors: moy rh. J Gastrointest Oncol. 2025 Apr 30;16(2):671-678. doi: 10.21037/jgo-2024-925. Epub 2025 Apr 27. J Gastrointest Oncol. 2025. PMID: 40386615 Free PMC article.
Phase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406).
Krishnamurthy A, Wang H, Rhee JC, Davar D, Moy RH, Ratner L, Christner SM, Holleran JL, Deppas J, Sclafani C, Schmitz JC, Gore S, Chu E, Bakkenist CJ, Beumer JH, Villaruz LC. Krishnamurthy A, et al. Among authors: moy rh. Cancer Chemother Pharmacol. 2025 Jan 22;95(1):27. doi: 10.1007/s00280-024-04745-6. Cancer Chemother Pharmacol. 2025. PMID: 39841295 Clinical Trial.
A CXCR4 partial agonist improves immunotherapy by targeting polymorphonuclear myeloid-derived suppressor cells and cancer-driven granulopoiesis.
Qian J, Ma C, Waterbury QT, Zhi X, Moon CS, Tu R, Kobayashi H, Wu F, Zheng B, Zeng Y, Zheng H, Ochiai Y, White RA, Harle DW, LaBella JS, Zamechek LB, Hu LZ, Moy RH, Han AS, Daugherty B, Lederman S, Wang TC. Qian J, et al. Among authors: moy rh. bioRxiv [Preprint]. 2024 Oct 11:2024.10.09.617228. doi: 10.1101/2024.10.09.617228. bioRxiv. 2024. PMID: 39416177 Free PMC article. Preprint.
First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial.
Cytryn SL, Moy RH, Cowzer D, Shah RH, Chou JF, Joshi SS, Ku GY, Maron SB, Desai A, Yang J, Sugarman R, Rao D, Goldberg Z, Charalambous C, Lapshina M, Antoine A, Socolow F, Trivedi N, Capanu M, Gerdes H, Schattner MA, Simmons M, Lacouture ME, Paroder V, Tang LH, Shia J, Ilson DH, Solit DB, Berger MF, Janjigian YY. Cytryn SL, et al. Among authors: moy rh. Lancet Oncol. 2023 Oct;24(10):1073-1082. doi: 10.1016/S1470-2045(23)00358-3. Epub 2023 Sep 1. Lancet Oncol. 2023. PMID: 37666264 Free PMC article. Clinical Trial.
39 results